NCT07254793
Prophylactic DLI-X for Leukemia Relapse After HCT
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Nov 30, 2026 to Oct 26, 2026
- Site details revised
Notable Enrollment increased: 94 → 180 participants Show 5 more changesShow less
- Primary endpoint(s) modified
- Start date: Oct 31, 2026 to Nov 30, 2026
- Eligibility criteria shortened, about 14 words
- Interventions modified
- Study title shortened, about 2 words
- Notable Start date: May 31, 2026 to Oct 31, 2026v3
- Notable Start date: Feb 28, 2026 to May 31, 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive pro-DLI-X.
Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive standard DLI-X.
Biologicals: Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI
Sites
1 site in 1 country
- The University of Arizona Cancer CenterTucson, Arizona, United States